Camizestrant

Camizestrant (CAS No.: 2222844-89-3) is a synthetic nonsteroidal selective estrogen receptor antagonist and degrader (SERD), with the development code AZD9833. It is mainly used for laboratory research on estrogen receptor α (ERα) signaling in oncology-related contexts, particularly for ER-positive/HER2-negative breast-derived research models. By binding to ERα, it antagonizes ligand-dependent activation, inhibits coactivator recruitment, and induces receptor conformational changes and destabilization, thereby promoting proteasome-mediated receptor degradation and weakening ER-driven transcriptional programs and related proliferative pathways. In in vitro studies, this compound typically shows subnanomolar to low-nanomolar potency in ERα degradation and inhibition of estradiol-stimulated proliferation, making it suitable for evaluating key parameters such as nuclear receptor pathway regulation, target occupancy, and functional antagonism; in animal xenograft models, systemic exposure based on appropriate dosing regimens can be used to verify phenotypic changes caused by ER pathway inhibition, providing evidence for pathway validation and pharmacological research. Typical applications include cell-level ER pathway regulation and gene expression analysis, assessment of receptor turnover and degradation kinetics, and use as a reference SERD in screening cascades and mechanistic comparison studies; the specific concentration or dose used in an experiment should be optimized and adjusted according to the experimental design, model characteristics, and research objectives. This product is for biomedical research and drug discovery-related experimental use only, and is not intended for clinical, diagnostic, or other non-research purposes.